Since empagliflozin alleviated both cerebral microvascular and cognitive impairment in a mixed mouse model of diabetes mellitus and Alzheimer’s disease, there is mounting evidence that SGLT-2 inhibitors have neuroprotective potential (Hierro-Bujalance et al. 2020). The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.